- Investigators Yes
- Outcome assessors Yes
- Intention-to-treat Yes
- Follow-up period 3-year period
- Post bronchodilator FEV₁
    - Stage IV (<30%)
        - Number 937
        - Age 64,2±7,8
        - Sex(M) 83%
    - Stage III (30% to <50%)
        - Number 3,017
        - Age 65,4±8,1
        - Sex(M) 76%
    - Stage II (50% to <80%)
        - Number 2,156
        - Age 64,9±8,7
        - Sex(M) 72%
        - + ≥80% 28 Pts
- Ethnicity
- Inclusion
    - Male or female aged 40~80 yrs
    - Current or exsmokers with a smoking history of ≥10 pack yrs
    - FEV₁≤60% pred, ≤10% reversibility in predicted FEV₁ and a FEV₁/FVC ratio ≤70%
    - An established history of COPD
- Exclusion
    - Current diagnosis of asthma or respiratory disorders other than COPD
    - Chest radiograph indicating diagnosis other than COPD
    - Had a lung-volume reduction surgery and/or a lung transplant
    - Requirement for LTOT at start of study >12 h/day
    - Receiving long-term oral corticosteroid therapy
    - Serious, uncontrolled disease likely to interfere with the study and/or cause death within the
    - 3-yr study period
- Intervention
    - Placebo group: placebo
    - Salmeterol alone: Salmeterol 50 μg twice daily
    - Fluticasone alone: Fluticasone propionate, 500 μg, twice daily
    - Salmeterol and Fluticasone: Salmeterol 50 μg plus Fluticasone propionate, 500 μg, twice daily

### Result (Stage II)
| Item                         | Placebo group | Salmeterol alone | Fluticasone alone | Salmeterol and Fluticasone |
| :--------------------------- | :------------ | :--------------- | :---------------- | :------------------------- |
| number                       | 535           | 522              | 537               | 562                        |
| Withdrawal rate              | 35%           | 27%              | 32%               | 27%                        |
| Mortality                    | 11.4%         | 9.2%             | 9.9%              | 7.8%                       |
| Moderate/severe exacerbation rates | 0.82/year     | 0.71/year        | 0.68/year         | 0.57/year                  |
| Adjusted mean FEV₁ (after 3 years) | 1,522         | 1,589            | 1,568             | 1,623                      |
| Rate of decline in FEV₁      | -60           | -40              | -46               | -44                        |
| Health status (SQRQ)         | -1,3          | -1,5             | -2,1              | -3,7                       |
| Treatment interaction        |               |                  |                   |                            |
| Adverse events               | 470 (87%)     | 471 (89%)        | 481 (88%)         | 487 (86%)                  |
| Probability of Pneumonia     | 10.6          | 9.4              | 12.8              | 15.3                       |

Definition: Moderate/severe exacerbation is defined as one requiring treatment with systemic corticosteroids and/or antibiotics. A severe exacerbation is an exacerbation requiring hospitalization.

P
I
C
O
및
근
거
표

7) 다군 환자에서 흡입지속성항콜린제 또는 흡입24시간지속성베타-2작용제를 사용하거나 ICS/LABA 복합제를 사용한다. 약제 간의 우열은 없으므로 환자의 선호도와 부작용을 고려하여 약물을 선택한다(근거수준: 높음, 권고강도: 강함).

### 근거표 7-1; Indacaterol vs tiotropium
| 연구수 | 연구설계 | 비뚤림 위험 | 비일관성 | 비직접성 | 비정밀 | 출판 비뚤림 | 근거수준 |
| :----- | :------- | :---------- | :------- | :------- | :------- | :---------- | :------- |
| 2      | 무작위대조군 | 없음        | 없음     | 없음     | 없음     | 없음        | 높음     |

<PAGE>111